ClinicalTrials.gg

Program

vutiglabridin

Also written as “HSG4112” and “Vutiglabridin”.

Its studies are mostly in Obesity · Parkinson Disease · Osteoarthritis, Knee, led by Glaceum.

Furthest: phase 2, since Jan 5, 20227 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Glaceum71 open or runningphase 2since Jan 5, 2022Dec 16, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2020First study: phase 1 study in ObesityFirst studyNCT04703764 · 40 enrolled · South Korea
  2. Jan 18, 20212 phase 1 studies in ObesityNCT04733001, NCT04732988
  3. Jan 5, 2022Phase 2 study in ObesityNCT05197556 · 81 enrolled · Korea, Republic of
  4. Mar 25, 2022Phase 1 study in ObesityNCT05310032 · 36 enrolled · Korea, Republic of
  5. Mar 18, 2024Phase 2 study in Parkinson DiseaseNCT06329141 · 99 enrolled · South Korea
  6. Feb 20, 2025Phase 2 study in Osteoarthritis, KneeNCT06845553 · 60 planned · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06845553Osteoarthritis, Knee · South Korea2RecruitingJul 31, 202660
NCT06329141Parkinson Disease · South Korea2CompletedDec 16, 202599
NCT05310032Obesity · Korea, Republic of1CompletedDec 12, 202236
NCT05197556Obesity · Korea, Republic of2CompletedDec 31, 202281
NCT04732988Obesity · Korea, Republic of1CompletedMay 24, 202190
NCT04733001Obesity · Korea, Republic of1CompletedFeb 10, 202112
NCT04703764Obesity · South Korea1CompletedJan 20, 202240

How it is read

Names in the registry

  • “HSG4112”, 5 entries
  • “Vutiglabridin”, 2 entries

Codes read as this program: HSG4112.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.